ProCE Banner Activity

Islatravir Effects on Lymphocyte Counts in HIV Treatment and Prevention

Capsule Summary
Conference Coverage

Overall, in HIV prevention and treatment trials, islatravir was associated with dose-dependent decreases from baseline in mean total lymphocyte and CD4+ counts. In prevention studies, lymphocyte counts returned to levels comparable to control after islatravir discontinuation.

Released: February 27, 2023

Expiration: February 26, 2024

No longer available for credit.



Supported by educational grants from

Gilead Sciences, Inc.

Janssen Therapeutics, Division of Janssen Products, LP

Merck & Co., Inc.

ViiV Healthcare